Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 321

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 321
---
 investment banking.

Notwithstanding our management team’s past experiences, past performance is not a guarantee that we will provide an attractive return to our stockholders from the Business Combination. You should not rely on the historical record of our management’s performance as indicative of our future performance. See “Risk Factors-Past performance of our management team may not be indicative of future performance of an investment in us, and we may be unable to provide positive returns to stockholders.”

Members of our team directly or indirectly own Founder Shares and/or private placement warrants and, accordingly, may have a conflict of interest in determining whether the Business Combination is appropriate. Further, each of our officers and directors have a conflict of interest with respect to evaluating the Business Combination because the retention or resignation of any such officers and directors was included by Liminatus as a condition to the Business Combination.

Our officers, directors and strategic advisors have agreed not to participate in the formation of, or become an officer, director or strategic advisor of, any other special purpose acquisition company with a class of securities registered under the Exchange Act without our prior written consent, which will not be unreasonably withheld.

Number and Terms of Office of Officers and Directors

The Iris Board consists of four members and is divided into two classes with only one class of directors being elected in each year, and with each class (except for those directors appointed prior to Iris’s first annual meeting of stockholders) serving a two-year term. In accordance with Nasdaq corporate governance requirements, Iris is not required to hold an annual meeting until one year after its first fiscal year end following its listing on Nasdaq. The term of office of the first class of directors, consisting of Messrs. Peretz and Fernandez, will expire at our first annual meeting of stockholders. The term of office of the second class of directors, consisting of Mr. Nanani, will expire at the second annual meeting of stockholders. Mr. Shah will serve until Iris’s next annual meeting of stockholders, when he is expected to stand for election by a vote of Iris’s stockholders. Iris’s officers are appointed by the Iris Board and serve at the discretion of the Iris Board, rather than for specific terms of office.

The Iris Board is authorized to appoint officers as it deems appropriate pursuant to the Iris Certificate of Incorporation.

<div align='center'>169</div>

TABLE OF CONTENTS

The Iris Board is authorized to appoint persons to the offices set forth in Iris’s Existing Bylaws. The Existing Bylaws provide that Iris’s officers consist of